Raymond James Downgrades Acceleron Pharma (XLRN) to Market Perform
Tweet
Share
E-mailGet Alerts XLRN Hot Sheet
Price: $178.75 --0%
Rating Summary:
11 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 9 | New: 11
Rating Summary:
11 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 9 | New: 11
Join SI Premium – FREE
Raymond James analyst Danielle Brill downgraded Acceleron Pharma (NASDAQ: XLRN) from Strong Buy to Market Perform.
For an analyst ratings summary and ratings history on Acceleron Pharma click here. For more ratings news on Acceleron Pharma click here.
Shares of Acceleron Pharma closed at $174.35 yesterday.
You May Also Be Interested In
- Baird Downgrades Darden Restaurants (DRI) to Neutral
- Recession impacts on Williams-Sonoma (WSM) 'appear underestimated'
- Credit Suisse Double Downgrades Evergy (EVRG) to Underperform
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
